Breaking

Public HealthFood Insecurity and Mental Health in South Africa Linked in New Survey ● Public HealthDirect-to-Consumer Microbiome Tests Face Regulatory Gaps, Review Finds ● PsychiatryREACH+ trial tests relapse prevention strategies in anorexia nervosa ● Medical InformaticsAToP framework maps EHR Transformer readmission risk to temporal patterns ● Public HealthFemale Health Volunteers in Nepal Show Readiness for Tobacco Cessation Counseling ● HematologyUganda study finds high antifolate resistance in children with sickle cell anaemia ● Infectious DiseaseSMC Sentinel Surveillance Detects Gaps and Emerging Resistance in Northern Kenya ● GeneticsIndirect Genetic Effects in ADHD and ASD Traits Across Development ●

Public HealthFood Insecurity and Mental Health in South Africa Linked in New Survey ● Public HealthDirect-to-Consumer Microbiome Tests Face Regulatory Gaps, Review Finds ● PsychiatryREACH+ trial tests relapse prevention strategies in anorexia nervosa ● Medical InformaticsAToP framework maps EHR Transformer readmission risk to temporal patterns ● Public HealthFemale Health Volunteers in Nepal Show Readiness for Tobacco Cessation Counseling ● HematologyUganda study finds high antifolate resistance in children with sickle cell anaemia ● Infectious DiseaseSMC Sentinel Surveillance Detects Gaps and Emerging Resistance in Northern Kenya ● GeneticsIndirect Genetic Effects in ADHD and ASD Traits Across Development ●

Advertisement

Rare Disease

Clinical evidence, research, and medical intelligence in Rare Disease.

Advertisement

Rare Disease · MedCity

BioMarin Pays $70M for Long-Acting Fabry Enzyme Therapy

BioMarin bought global rights to a long-acting Fabry enzyme therapy that could extend treatment to patients outside Galafold’s reach.

By Dr. A. Nikhil Krishnan, MBBS · Oct 30, 2026 · 5 min read

Rare Disease·ACC-PRO

Ambrose buys AM-Pharma for $181M, betting on HPP asset ilofotase alfa

Ambrose Healthcare bought AM-Pharma for up to $181 million, centering the deal on ilofotase alfa and a rare…

Rare Disease

Clinical evidence, research, and medical intelligence in Rare Disease.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.

Advertisement

Most Read

Medicine World Foundation Alerts

Daily Clinical Dispatch

Receive peer-screened summaries across 17 clinical specialties delivered to your inbox every morning.

Trending Topics Clinical Keywords

#GLP-1 #Lecanemab #CAR-T #SepsisBundle #Semaglutide #SGLT2 #LongCOVID #AntibioticStewardship #AIDiagnostics #Statins

Advertisement

Advertisement